News Pfizer's weekly haemophilia drug backed for NHS use Some patients in England living with severe haemophilia B will soon be able to do away with need for regular infusions.
News Pfizer bags EU okay for haemophilia drug Hympavzi Pfizer's Hympavzi has become the first once-weekly subcutaneous treatment for people living with severe haemophilia B in the EU
News Pfizer rounds out haemophilia portfolio with FDA approval Pfizer’s anti-TFPI antibody marstacimab has been approved by the FDA to treat haemophilia, becoming the pharma group’s second new therapy for the blood disorder this year.
News NHS "isn't delivering equitable care for rare diseases" A Genetic Alliance UK report claims the NHS is failing to meet the needs of many of the 3.5 million people in the country who live with rare diseases.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
